FDA/Generic Communications Plan Restoring Best Of Past Practices
This article was originally published in PharmAsia News
Office of Generic Drugs wants to allow project managers to inform sponsors of major deficiencies before ‘complete response’ letter as part of ‘go/no go’ effort.
You may also be interested in...
FDA offers two-prong criteria to determine which ANDAs would get priority in review system; industry wants expanded classification that includes drug shortages.
“We might as well talk to an answering machine,” sponsor complains at GDUFA public meeting.
CDER staff manual outlines seven categories of submissions that can qualify for expedited review, including some ANDAs with patent certifications and supplements that have the potential to create an “extraordinary hardship” for a sponsor if not addressed quickly.